OBR Daily Commentary

forumImage

MacroGenics Thrives Following Positive Breast Cancer Results

(BioSpace) May 16, 2019 - The trial evaluated margetuximab in patients with HER2-positive metastastic breast cancer who had already been treated with anti-HER2-targeted therapies.

(Posted: May 17, 2019)

quotesTrastuzumab deruxtecan makes Margetixumab clinically irrelevant quotes

Read Article arrow
Add Comment 1 Comment
forumImage

New Insights Into Treatment Targets For Men With Advanced Prostate Cancers

(Huntsman Cancer Institute) May 13, 2019 - In the largest study of its kind, more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies.

Tomasz M. Beer, MD, FACP (Posted: May 14, 2019)

quotesWhile it is undoubtedly exciting to find that more than half of the men with advanced prostate cancer have a genomic alteration which we may be able to match to a drug, this is a very long way indeed from demonstrating a patient benefit. There are countless examples of targeted drugs that yielded little or no benefit in prostate cancer and many other malignancies. This is an important first step, but what is needed next are careful studies that demonstrate what drugs can help which patients based on genomic findings. The routine use of such approaches outside of a clinical trial is not yet warranted with some very specific and not common exceptions. This is not yet an argument for molecularly directed therapy for more than half of our patients. quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Trastuzumab Deruxtecan Demonstrated Clinically-Meaningful Response In Patients With Refractory HER2-positive Metastatic Breast Cancer, A Population With High Unmet Need

(AstraZeneca) May 8, 2019 - AstraZeneca and Daiichi Sankyo Company, Limited today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

Debu Tripathy, MD (Posted: May 08, 2019)

quotesThe development of testing of new antibody-drug conjugates (ADCs, also known as immunoconjugates) is rapidly growing as these agents allow for more cancer cell-specific drug delivery and the use of more potent cytotoxic drugs than can be given by conventional administration. Every such drug has its own "operating characteristics" depending on the antibody/antigen system used, the nature of the linker attaching the antibody to the active drug and the cytotoxic "payload". In the case of trastuzumab deruxtecan, impressive response rates were shown in pretreated patients with HER2+ breast cancer the Phase I setting. Responses nearing 50% were even shown in a separate cohort of patients who had lower HER2 expression in the negative range by conventional definitions. While the results of the Phase II trial have not yet been made public, there is significant enthusiasm as the Phase III registration trials for both HER2+ and HER2-low get off the ground.quotes

Read Article arrow
Add Comment 2 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...